Posts by KCAS Bio

PATTERN_ORANGE_1320x780 Blogs
Read article Navigating the FDA’s Tobacco Regulations

The FDA has regulated cigarettes, smokeless and loose tobacco since 2009 under the Tobacco Control Act. In 2016, the FDA finalized a rule for the regulation of all tobacco products, making it illegal to sell e-cigarettes, cigars and hookah tobacco to anyone under 18 and requiring retailers to check photo…

PATTERN_BLUE_1320x780 Blogs
Read article Analysis of Unstable Compounds at KCAS

Several important classes of drugs are inherently unstable in biological fluids. Examples include alkylating agents, cytostatic nucleosides, drugs with ester, aldehyde, thiol, nitroxyl or lactone functional groups, and small molecule compounds with unstable metabolites, such as acylglucuronides. The rate at which an analyte degrades in blood, other biological fluids, or…

PATTERN_ORANGE_1320x780_2 Blogs
Read article Validating Drug Assays in Tissues

Designing a tissue assay in accordance to the FDA bioanalytical method validation (BMV) guidance involves three key questions. First, can control tissue be easily obtained in bulk quantities or should a surrogate tissue approach be considered? Second, what sample processing procedures should be considered relative to the known stability of…

PATTERN_BLUE_1320x780 Blogs
Read article Quality Assurance at KCAS

In pursuit of KCAS’ Mission to provide reliable and defendable data, quality is one of our core values. It is the responsibility of every employee to provide an always improving, high-level performance in all we do. Our independent Quality Assurance Unit (QAU) assures management that Operations is performing in conformance…

PATTERN_BLUE_1320x780 Blogs
Read article The Value of Deuterated Internal Standards

Surprisingly, there are a number of drug development companies that do not obtain stable isotope-labeled internal standards (SIL-IS) for their bioanalytical methods. Instead they settle for using a surrogate internal standard (a compound that closely resembles the measured analyte) which can lead to unreliable data and be detrimental to a…

PATTERN_AMBER_1320x780_3 Blogs
Read article Feasibility Studies at KCAS: Avoiding Unwanted Surprises

Like the old adage, “you get out of it what you put into it,” good study design is a prerequisite of good data. To boost the chances of generating accurate and informative facts over the course of a study, it is key to consider all of the supporting parameters that…

PATTERN_AMBER_1320x780 Blogs
Read article Applying GLP Standards to Sub-Ambient Sample Storage at KCAS

There is regulatory requirement that the cumulative time a frozen pharmacokinetic sample has been thawed – from the time it’s removed from the freezer to the time it’s returned – be documented. Freeze/thaw cycle data is not deemed sufficient alone, since a study sample might have been thawed for extended…

PATTERN_ORANGE_1320x780_2 Blogs
Read article Common Rule – Who decides what happens to your samples?

The Department of Health and Human Services (HHS) has issued long awaited, comprehensive update on how medical research should be conducted. The Common Rule, 45 CFR 46 subpart A, issued 26 years ago and established basic protections for human subjects in research conducted by or supported by the HHS and…

KCAS-blog-thumb_David-vs-Goliath Blogs
Read article Boutique CROs: Being David in a land of Goliaths

In today’s drug development arena, massive, multinational CROs dominate the industry. They offer a “one stop shop” suite of services covering Early Development to Phase IV Clinical Trials and everything in between. Although multinational…